Mallinckrodt completed the acquisition of Therakos from The Gores Group for $1.325bn.

Mallinckrodt, a specialty biopharmaceutical company, completed the acquisition of Therakos, a company delivering extracorporeal photopheresis systems, from The Gores Group, a private equity firm specializing in acquiring and partnering with mature and growing businesses, for $1.325bn. "This latest transaction demonstrates our ongoing commitment to building a strong, sustainable and profitable Hospital growth business to drive revenue and earnings for shareholders and, through the Therakos Immunotherapy Systems, provide an immunotherapy treatment for patients who may have exhausted other therapies, with significant potential to treat a variety of complex disease states and conditions. In the past two years we've transformed Mallinckrodt into a leading specialty biopharmaceutical company built on highly durable growth platforms with a broad and diverse product portfolio, and this acquisition continues that journey," Mark Trudeau, Mallinckrodt President and CEO.